•  
  •  
  •  
  •  

2025-09-28 19:14:01

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark

Keywords Selected:  SyngeneInternational

Research

  • Q4FY22 Result Update - Syngene International - ICICI Direct
  • Q3FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Q3FY22 Result First cut - YES Securities
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

Stock Report

  • USFDA conducts GCP inspection at Syngene International Ltd's facility at Semicon Park, Bengaluru
  • Syngene International Ltd updates on USFDA inspection at Biocon Park, SEZ, Bengaluru
  • Syngene International Ltd recommends final dividend of Rs. 1.25
  • Syngene International Ltd Q4 FY2025 consolidated profit at Rs. 183.3 crores
  • Syngene International Limited appoints Mr. Peter Bains as MD & CEO
  • Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.
  • Syngene acquires its First Manufacturing Facility in the US
  • Syngene International Ltd updates on USFDA inspection at Bengaluru facilities
  • Syngene International Ltd consolidated Q3FY25 profit up at Rs. 131.1 crores
  • Syngene International Ltd Q2 FY2025 consolidated PAT at Rs. 106.1 crores
  • Syngene International Ltd Q1 FY2024-25 consolidated net profit declines to Rs. 75.7 crores
  • Syngene International Ltd recommends final dividend of Rs. 1.25
  • Syngene International Ltd reports Rs. 188.6 crores consolidated PAT in Q4 FY2024
  • Syngene International Ltd consolidated Q3 FY2024 net profit at Rs. 111.5 crores
  • Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd
  • Syngene International Ltd Q2 FY2024 consolidated PAT higher at Rs. 116.5 crores
  • Syngene International Ltd posts consolidated PAT of Rs. 93.4 crores in Q1 FY2024
  • Stelis Biopharma enters into a binding term sheet with Syngene International Ltd to divest its Unit 3 multi-modal facility
  • Syngene International Ltd recommends final dividend of Rs. 1.25
  • Syngene International Ltd's consolidated profit for Q4 FY2023 rises to Rs. 178.7 crores
  • Syngene International Ltd reports consolidated PAT of Rs. 109.7 crores in Q3 FY23
  • Syngene International Ltd update on USFDA Inspection of Biologics facility
  • Syngene International Ltd consolidated Q2 FY2023-22 net profit climbs to Rs. 102 crores
  • Syngene International Ltd consolidated Q1 FY23 PAT drops to Rs. 73.9 crores

Latest Post

  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024